Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease.

1.0 Checklist for Patient Eligibility and Necessary Information 2.0 Objectives 3.0 Background and Rationale 4.0 Study Design 5.0 Patient Eligibility 6.0 Treatment Plan 7.0 Patient Evaluation 8.0 Evaluation during Study 9.0 Statistical Considerations 10.0 Study Interpretation 11.0 Off Study Criteria 12.0 Records to Be Kept 13.0 Reporting Requirements 14.0 Informed Consent 15.0 References Appendix I